Educational information, not medical advice — ask your doctor or midwife.
Track Keishibukuryogan (Kampo) with reminders and record whether it helped, in the app.
Keishibukuryogan is one of the most widely prescribed Kampo formulas in Japan, officially listed in the Japanese Pharmacopoeia and covered under national health insurance. It combines five herbs — cinnamon bark, poria mushroom, peony root, peach kernel, and moutan bark — into a balanced formula designed to move stagnant blood and ease inflammation. In Traditional Chinese Medicine it is known as Gui Zhi Fu Ling Wan, where it has been in use for roughly 2,000 years.
The formula works by improving microcirculation and reducing what Kampo calls 'blood stasis' — a pattern linked to poor pelvic blood flow, hormonal imbalance, and chronic low-grade inflammation. Peach kernel and moutan bark have demonstrated anti-inflammatory and platelet-inhibiting effects, while cinnamon bark supports vascular tone and peony root helps ease smooth muscle spasm. Together they create a mild, sustained effect on gynecological tissues without the sharp hormonal signals of pharmaceutical agents.
In Japan, standardized extract granules (such as Tsumura TJ-25) are the most common prescribed form and have been used in clinical trials. Tablets offer similar convenience. Traditional decoctions brewed from raw herbs are still used by some practitioners but are less standardized and harder to dose consistently.
This formula originates from the 'Jin Gui Yao Lue' (Essentials from the Golden Cabinet), a foundational Chinese medical text compiled by Zhang Zhongjing around 200 CE. It was adopted into Japanese Kampo practice centuries later and today is among the top-ten most prescribed Kampo medicines in Japan, used by licensed physicians as part of mainstream integrative care.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.